Work

Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report

Year: 2026

Type: article

Abstract: Sorafenib is an oral multikinase inhibitor approved for advanced hepatocellular carcinoma, renal cell carcinoma, and maintenance therapy in selected patients with FMS-like tyrosine kinase (FLT3)-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. We report the case of a 35-year-old woman with FLT3 internal tandem duplication (FLT3-ITD) and nucleophosmin 1 (NPM1)-positive acute myeloid leukemia (AML) who developed painful hyperkeratotic plantar plaques approximately eight weeks after initiating sorafenib therapy. Clinical examination revealed multiple symmetrical hyperkeratotic plaques involving the pressure-bearing areas of both soles, associated with pain and tenderness, resulting in significant impairment of daily activities. She was diagnosed with sorafenib-induced hand-foot skin reaction (HFSR) and was managed with topical keratolytic and corticosteroid therapy. This case highlights the importance of early recognition and prompt management of sorafenib-induced HFSRs to minimize morbidity and maintain oncological treatment.

Source: Cureus

DOI: 10.7759/cureus.116921

Authors: Christa Davis, Arun Vignesh, Sudha Rangarajan, Murugan Sundaram, Adikrishnan Swaminathan

Institution: Sri Ramachandra Institute of Higher Education and Research

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7214405467